A PHASE 3, MULTICENTER, DOA PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF IVOSIDENIB IN PARTICIPANTS = 18 YEARS OF AGE WITH LOCALLY ADVANCED OR METASTATIC CONVENTIONAL CHONDROSARCOMA WITH AN IDH1 MUTATION, UNTREATED OR PREVIOUSLY

Registry ID

CL3-95031-007

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

SERVIER CANADA INC

Start date

2025-11-10

Last update

2024-05-16

Conditions

• CHONDROSARCOMA
• CANCER

Related clinical trials

• ProActIF-01 Trial: Feasibility Study of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Digestive Cancers
• VEDOLIZUMAB FOR THE PREVENTION OF IMMUNE CHECKPOINT INHIBITOR RELATED TO DIARREA OR COLITIS IN PATIENTS WITH CANCER. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL
• TRIPTORELIN AND PROTECTION OF OVARIAN RESERVE IN ADOLESCENTS AND YOUNG ADULTS WITH CANCER
• OPTIMAL PRECISION THERAPIES TO CUSTOMISE CARE IN CHILDHOOD AND ADOLESCENT CANCER (OPTIMISE)
• AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOSULY ENROLLED IN A GENENTECH AND/OR F.HOFFMANLA ROCHE SPONSORED STUDY
• PREVENTION OF THROMBOEMBOLISM WITH RIVAROXABAN IN GENITOURINARY CANCER PATIENTS RECEIVING SYSTEMIC THERAPY: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL

View on source registry